#	Pagina
attuale pagina	/open-h2020/projects/219922/index.html
-1	/open-h2020/per-topic/noncompact/list/index.html
-2	/open-h2020/per-topic/c3isp/list/index.html

Opendata, web and dolomites

ELEVATE SIGNED

Early detection of cervical cancer in hard-to-reach populations of women through portable and point-of-care HPV testing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

ELEVATE project word cloud

Explore the words cloud of the ELEVATE project. It provides you a very rough idea of what is the project "ELEVATE" about.

detection reflection risk preventive sampling efficient science highlights generate multidisciplinary lack hard disseminate caribbean screened self electrical infections belgium 85 countries accessible fundamental comprising strategies american social elevate cultural portugal rapid relying participatory infer societal women human fourth implications populations technological ethnic vaccination made cervical worl investigations hpv differences cancer economic worldwide coverage primary ecuador resource latin complemented brazil care genomic base conduct understand 4th papillomavirus hamper successful shown health compatible proteomic barriers point combined manufactures screening community adequacy mortality attendance programs global trained reducing portable precancer outlets integrant burden marketable occurring team incidence reduce experts

Project "ELEVATE" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITEIT GENT Organization address address: SINT PIETERSNIEUWSTRAAT 25 city: GENT postcode: 9000 website: http://www.ugent.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Total cost	3˙999˙310 €
EC max contribution	3˙301˙990 € (83%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2023-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITEIT GENT UNIVERSITEIT GENT Organization address address: SINT PIETERSNIEUWSTRAAT 25 city: GENT postcode: 9000 website: http://www.ugent.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (GENT)	coordinator	1˙518˙835.00
2	UNIVERSIDADE NOVA DE LISBOA UNIVERSIDADE NOVA DE LISBOA Organization address address: CAMPUS DE CAMPOLIDE city: LISBOA postcode: 1099 085 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (LISBOA)	participant	419˙850.00
3	LABMAN AUTOMATION LIMITED LABMAN AUTOMATION LIMITED Organization address address: SEAMER HILL STOKESLEY city: MIDDLESBROUGH CLEVELAND postcode: TS9 5NQ website: www.labman.co.uk contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (MIDDLESBROUGH CLEVELAND)	participant	395˙420.00
4	UNIVERSITAT ROVIRA I VIRGILI UNIVERSITAT ROVIRA I VIRGILI Organization address address: CARRER DE ESCORXADOR city: TARRAGONA postcode: 43003 website: http://www.urv.cat contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (TARRAGONA)	participant	341˙802.00
5	UNIVERSIDAD DE CUENCA UNIVERSIDAD DE CUENCA Organization address address: 12 OF APRIL AVENUE city: CUENCA postcode: 1.01 website: http://rai.ucuenca.edu.ec/facultades/ciencias_medicas/medicas.htm contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EC (CUENCA)	participant	259˙900.00
6	FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. Organization address address: HANSASTRASSE 27C city: MUNCHEN postcode: 80686 website: www.fraunhofer.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (MUNCHEN)	participant	214˙577.00
7	microLIQUID sl microLIQUID sl Organization address address: Av. Uribarri 19-1 city: Arrasate-Mondragon postcode: 20500 website: www.microliquid.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (Arrasate-Mondragon)	participant	151˙605.00
8	CONSORCIO DE INVESTIGACION SOBRE VIH SIDA TB CISIDAT CONSORCIO DE INVESTIGACION SOBRE VIH SIDA TB CISIDAT Organization address address: AV. TEOPANZOLCO 408 TORRE C 201 REFORMA city: CUERNAVACA MORELOS postcode: 62260 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	MX (CUERNAVACA MORELOS)	participant	0.00
9	FUNDACAO PIO XII FUNDACAO PIO XII Organization address address: RUA ANTENOR DUARTE VILELA, 1331 city: BARRETOS postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BR (BARRETOS)	participant	0.00

Map

Project objective

Cervical cancer is the 4th most common cancer in women worlThe ELEVATE project sets a multidisciplinary team comprising manufactures and experts from Europe and the Community of Latin American and Caribbean States, to improve the global adequacy and coverage of cervical cancer screening, particularly to specific populations of women that by not being regularly screened (hard-to-reach populations) are at higher-risk to develop cervical cancer. Although Cervical cancer is still the fourth most common cancer in women worldwide, with up to 85% of the burden occurring in developing countries, preventive vaccination against human papillomavirus and early detection of precancer in screening programs has shown to be successful in reducing cancer incidence and mortality.1–3 However, different challenges hamper a global implementation of such programs and are in the base of women’s non-attendance to screening. This highlights the lack of reflection of ethnic, cultural and resource differences from different populations in current cervical cancer screening. In ELEVATE it is proposed to conduct social science investigations to identify hard-to-reach women in Belgium, Brazil, Ecuador and Portugal, to address their barriers to screening and to design strategies to make primary screening more accessible to them, and therefore, contribute to reduce the global burden of cervical cancer. This will be complemented with fundamental and technological research to develop an efficient and marketable test for the combined genomic and proteomic detection of high-risk HPV infections in those populations. The test will be made portable, low-cost, compatible with self-sampling, point-of-care and generate rapid and easy-to-understand results, without relying on electrical outlets or trained health personnel. Integrant part of the proposal is also to infer and disseminate the societal, economic implications of the developed strategies using a hard-to-reach community-based participatory research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ELEVATE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ELEVATE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More